James Patrick Mackin
Net Worth

Last updated:

What is James Patrick Mackin net worth?

The estimated net worth of Mr. James Patrick Mackin is at least $23,552,675 as of 30 Apr 2021. He owns shares worth $5,438,703 as insider, has earned $8,303,972 from insider trading and has received compensation worth at least $9,810,000 in Artivion, Inc..

What is the salary of James Patrick Mackin?

Mr. James Patrick Mackin salary is $1,090,000 per year as Chairman, Pres & Chief Executive Officer in Artivion, Inc..

How old is James Patrick Mackin?

Mr. James Patrick Mackin is 58 years old, born in 1967.

What stocks does James Patrick Mackin currently own?

As insider, Mr. James Patrick Mackin owns shares in one company:

Company Title Shares Price per share Total value
Artivion, Inc. (CRY) Chairman, Pres & Chief Executive Officer 304,178 $17.88 $5,438,703

What does Artivion, Inc. do?

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. Artivion Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

James Patrick Mackin insider trading

Artivion, Inc.

Mr. James Patrick Mackin has made 8 insider trades between 2016-2021, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 103,072 units of CRY stock on 13 Aug 2018. As of 30 Apr 2021 he still owns at least 304,178 units of CRY stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 45,734 N/A N/A
Option
StockOption(Right To Buy) 16,265 N/A N/A
Sale
Common Stock 16,265 N/A N/A
Purchase
Common Stock 7,500 N/A N/A
Purchase
Common Stock 5,000 $23.47 $117,355
Sale
Common Stock 50,000 $31.31 $1,565,700
Option
Common Stock 9,851 $31.8 $313,213
Sale
Common Stock 9,851 $31.8 $313,213
Option
Stock Options (Right to Buy) 9,851 $31.8 $313,213
Option
Stock Options (Right to Buy) 37,077 $32.22 $1,194,473
Sale
Common Stock 37,077 $32.22 $1,194,473
Option
Common Stock 37,077 $32.22 $1,194,473
Option
Common Stock 103,072 $10.24 $1,055,457
Sale
Common Stock 103,072 $10.24 $1,055,457
Option
Stock Options (Right to Buy) 103,072 $10.24 $1,055,457
Sale
Common Stock 42,675 $33.35 $1,423,382
Sale
Common Stock 81,950 $21.97 $1,800,687
Sale
Common Stock 43,050 $22.09 $951,061
Purchase
Common Stock 4,600 $10.94 $50,324
Purchase
Common Stock 5,400 $10.89 $58,806

Artivion key executives

Artivion, Inc. executives and other stock owners filed with the SEC:

  • Mr. David Ashley Lee CPA, CPA (60) Executive Vice President, Chief Operating Officer & Chief Financial Officer
  • Mr. James Patrick Mackin (58) Chairman, Pres & Chief Executive Officer
  • Mr. John E. Davis (60) Senior Vice President of Global Sales & Marketing
  • Ms. Jean F. Holloway Esq. (68) Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec.